Market Research Logo

NovoCure Ltd (NVCR) - Product Pipeline Analysis, 2018 Update

Summary

NovoCure Ltd (NovoCure) is an drug company that offers development and commercialization of novel therapies for tumor treating fields. The company’s pipeline products find application in cancer indications such as malignant melanoma, hepatocellular carcinoma, ovarian cancer, breast cancer and small cell lung cancer, among others. It also offers provides products for other indications such as glioblastoma and diagnosed glioblastoma, among others. Novocure owns and operates a research centre in Haifa, Israel; and operates along with its subsidiaries located in the US; Berlin, and Germany. The company has its operations in Japan and Switzerland. NovoCure is headquartered in St. Helier, the UK.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company NovoCure Ltd
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company


NovoCure Ltd Company Overview 6
NovoCure Ltd Company Snapshot 6
NovoCure Ltd Pipeline Products and Ongoing Clinical Trials Overview 6
NovoCure Ltd – Pipeline Analysis Overview 9
NovoCure Ltd - Key Facts 9
NovoCure Ltd - Major Products and Services 10
NovoCure Ltd Pipeline Products by Development Stage 11
NovoCure Ltd Ongoing Clinical Trials by Trial Status 13
NovoCure Ltd Pipeline Products Overview 15
Optune - Brain Metastasis 15
Optune - Brain Metastasis Product Overview 15
Optune - Brain Metastasis Clinical Trial 16
Optune - Breast Cancer 18
Optune - Breast Cancer Product Overview 18
Optune - Cervical Cancer 19
Optune - Cervical Cancer Product Overview 19
Optune - Colorectal Carcinoma 20
Optune - Colorectal Carcinoma Product Overview 20
Optune - Gastric Adenocarcinoma 21
Optune - Gastric Adenocarcinoma Product Overview 21
Optune - Hepatocellular Carcinoma 22
Optune - Hepatocellular Carcinoma Product Overview 22
Optune - Malignant Melanoma 23
Optune - Malignant Melanoma Product Overview 23
Optune - Mesothelioma 24
Optune - Mesothelioma Product Overview 24
Optune - Mesothelioma Clinical Trial 25
Optune - Non - Small Cell Lung Cancer 26
Optune - Non - Small Cell Lung Cancer Product Overview 26
Optune - Ovarian Cancer 27
Optune - Ovarian Cancer Product Overview 27
Optune - Ovarian Cancer Clinical Trial 28
Optune - Pancreatic Cancer 29
Optune - Pancreatic Cancer Product Overview 29
Optune - Pancreatic Cancer Clinical Trial 30
Optune - Pediatric Glioma 31
Optune - Pediatric Glioma Product Overview 31
Optune - Pediatric Glioma Clinical Trial 32
Optune - Prostate Cancer 33
Optune - Prostate Cancer Product Overview 33
Optune - Renal Adenocarcinoma 34
Optune - Renal Adenocarcinoma Product Overview 34
Optune - Squamous Non-Small Cell Lung Cancer 35
Optune - Squamous Non-Small Cell Lung Cancer Product Overview 35
Optune - Urinary Transitional Cell Carcinoma 36
Optune - Urinary Transitional Cell Carcinoma Product Overview 36
Optune Plus Bevacizumab - Recurrent Glioblastoma 37
Optune Plus Bevacizumab - Recurrent Glioblastoma Product Overview 37
Optune With Marizomib And Temozolomide - Glioblastoma 38
Optune With Marizomib And Temozolomide - Glioblastoma Product Overview 38
NovoCure Ltd - Key Competitors 39
NovoCure Ltd - Key Employees 40
NovoCure Ltd - Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 42
NovoCure Ltd, Recent Developments 42
Jul 02, 2018: Novocure Names Pritesh Shah As Chief Commercial Officer 42
Jun 04, 2018: Novocure to Present INNOVATE-3 Phase 3 Pivotal Trial Design in Recurrent Ovarian Cancer at the American Society of Clinical Oncology Annual Meeting 2018 42
May 31, 2018: Novocure Announces Changes to Its Board of Directors 42
May 28, 2018: Update on Mithra and Mayne Pharma’s Vaginal Contraceptive Ring Opportunity 43
Apr 26, 2018: Novocure Reports First Quarter 2018 Financial Results and Provides Company Update 44
Apr 17, 2018: Novocure Reports Positive Top-line Results from STELLAR Phase 2 Pilot Trial in Mesothelioma 45
Apr 13, 2018: Data on Tumor Treating Fields to Be Presented at American Association for Cancer Research Annual Meeting 46
Mar 20, 2018: NCCN Guidelines Recommend Optune in Combination with Temozolomide as a Category 1 Treatment for Newly Diagnosed Glioblastoma 46
Mar 15, 2018: Novocure Announces 35 Presentations on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2018 47
Feb 22, 2018: Novocure Announces Fourth Quarter and Full Year 2017 Financial Results 49
Appendix 52
Methodology 52
About GlobalData 55
Contact Us 55
Disclaimer 55
List of Tables
NovoCure Ltd Pipeline Products and Ongoing Clinical Trials Overview 6
NovoCure Ltd Pipeline Products by Equipment Type 7
NovoCure Ltd Pipeline Products by Indication 8
NovoCure Ltd Ongoing Clinical Trials by Trial Status 8
NovoCure Ltd, Key Facts 9
NovoCure Ltd, Major Products and Services 10
NovoCure Ltd Number of Pipeline Products by Development Stage 11
NovoCure Ltd Pipeline Products Summary by Development Stage 12
NovoCure Ltd Ongoing Clinical Trials by Trial Status 13
NovoCure Ltd Ongoing Clinical Trials Summary 14
Optune - Brain Metastasis - Product Status 15
Optune - Brain Metastasis - Product Description 15
Optune - Brain Metastasis - A Phase II Randomized Study of TTField Therapy (150 kHz) Versus Supportive Care in Non-small Cell Lung Cancer Patients with 1-5 Brain Metastases Following Optimal Standard Local Treatment 16
Optune - Brain Metastasis - Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma 16
Optune - Brain Metastasis - Pivotal, Open-label, Randomized Study of Radiosurgery with or without Tumor Treating Fields (TTFields) (150kHz) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC) 17
Optune - Breast Cancer - Product Status 18
Optune - Breast Cancer - Product Description 18
Optune - Cervical Cancer - Product Status 19
Optune - Cervical Cancer - Product Description 19
Optune - Colorectal Carcinoma - Product Status 20
Optune - Colorectal Carcinoma - Product Description 20
Optune - Gastric Adenocarcinoma - Product Status 21
Optune - Gastric Adenocarcinoma - Product Description 21
Optune - Hepatocellular Carcinoma - Product Status 22
Optune - Hepatocellular Carcinoma - Product Description 22
Optune - Malignant Melanoma - Product Status 23
Optune - Malignant Melanoma - Product Description 23
Optune - Mesothelioma - Product Status 24
Optune - Mesothelioma - Product Description 24
Optune - Mesothelioma - A Phase II Trial of Pemetrexed and Cisplatin or Carboplatin in Combination with TTFields (150 kHz) as First-line Treatment in Malignant Pleural Mesothelioma 25
Optune - Non - Small Cell Lung Cancer - Product Status 26
Optune - Non - Small Cell Lung Cancer - Product Description 26
Optune - Ovarian Cancer - Product Status 27
Optune - Ovarian Cancer - Product Description 27
Optune - Ovarian Cancer - A Phase III Pivotal Study of Tumor Treating Fields Concomitant with Weekly Paclitaxel in the Treatment of Platinum-resistant Ovarian Cancer: INNOVATE-3 28
Optune - Ovarian Cancer - An Open Label Pilot Study of the NovoTTF-100L(O) System (NovoTTF Therapy) (200 kHz) Concomitant with Weekly Paclitaxel for Recurrent Ovarian Carcinoma 28
Optune - Pancreatic Cancer - Product Status 29
Optune - Pancreatic Cancer - Product Description 29
Optune - Pancreatic Cancer - A Phase II Study of TTFields (150 kHz) Concomitant with Gemcitabine and TTFields Concomitant with Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma 30
Optune - Pancreatic Cancer - PANOVA - 3: A Phase III Study of TTFields with Gemcitabine and Nab-paclitaxel for Front - Line Treatment of Locally Advanced Pancreatic Adenocarcinoma (LAPC) 30
Optune - Pediatric Glioma - Product Status 31
Optune - Pediatric Glioma - Product Description 31
Optune - Pediatric Glioma - A Phase I Trial of the Optune NovoTTF-200A System with and without Concomitant Temozolomide and Bevacizumab in Pediatric Patients with High-grade Glioma (HUMC 1612) 32
Optune - Pediatric Glioma - Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-grade Glioma and Ependymoma 32
Optune - Prostate Cancer - Product Status 33
Optune - Prostate Cancer - Product Description 33
Optune - Renal Adenocarcinoma - Product Status 34
Optune - Renal Adenocarcinoma - Product Description 34
Optune - Squamous Non-Small Cell Lung Cancer - Product Status 35
Optune - Squamous Non-Small Cell Lung Cancer - Product Description 35
Optune - Urinary Transitional Cell Carcinoma - Product Status 36
Optune - Urinary Transitional Cell Carcinoma - Product Description 36
Optune Plus Bevacizumab - Recurrent Glioblastoma - Product Status 37
Optune Plus Bevacizumab - Recurrent Glioblastoma - Product Description 37
Optune With Marizomib And Temozolomide - Glioblastoma - Product Status 38
Optune With Marizomib And Temozolomide - Glioblastoma - Product Description 38
NovoCure Ltd, Key Employees 40
NovoCure Ltd, Subsidiaries 41
Glossary 54
List of Figures
NovoCure Ltd Pipeline Products by Equipment Type 7
NovoCure Ltd Pipeline Products by Development Stage 11
NovoCure Ltd Ongoing Clinical Trials by Trial Status 13

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report